Greenwich LifeSciences annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Greenwich LifeSciences Stock-Based Compensation Growth & History (GLSI)
Greenwich LifeSciences's stock-based compensation was $6.8M for fiscal 2025.
View full Greenwich LifeSciences company overviewGreenwich LifeSciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.8M | −$450,002 | −6.20% |
| 2024 | 2024-12-31 | $7.3M | $4.9M | +205.01% |
| 2023 | 2023-12-31 | $2.4M | $634,223 | +36.37% |
| 2022 | 2022-12-31 | $1.7M | $1.1M | +163.99% |
| 2021 | 2021-12-31 | $660,582 | −$17,406 | −2.57% |
| 2020 | 2020-12-31 | $677,988 | $483,045 | +247.79% |
| 2019 | 2019-12-31 | $194,943 | — | — |
Greenwich LifeSciences quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.5M | −$59,452 | −3.85% |
| Q1 2026 | 2026-03-31 | $1.5M | $0 | 0.00% |
| Q4 2025 | 2025-12-31 | $2.2M | −$3.3M | −60.31% |
| Q3 2025 | 2025-09-30 | $1.5M | $949,692 | +159.74% |
| Q2 2025 | 2025-06-30 | $1.5M | $949,692 | +159.74% |
| Q1 2025 | 2025-03-31 | $1.5M | $949,692 | +159.74% |
| Q4 2024 | 2024-12-31 | $5.5M | $4.9M | +820.03% |
| Q3 2024 | 2024-09-30 | $594,522 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $594,522 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $594,522 | $0 | 0.00% |
| Q4 2023 | 2023-12-31 | $594,522 | $0 | 0.00% |
| Q3 2023 | 2023-09-30 | $594,522 | −$165,051 | −21.73% |
| Q2 2023 | 2023-06-30 | $594,522 | $370,019 | +164.82% |
| Q1 2023 | 2023-03-31 | $594,522 | $429,255 | +259.73% |
| Q4 2022 | 2022-12-31 | $594,522 | $429,093 | +259.38% |
| Q3 2022 | 2022-09-30 | $759,573 | $594,522 | +360.21% |
| Q2 2022 | 2022-06-30 | $224,503 | $59,452 | +36.02% |
| Q1 2022 | 2022-03-31 | $165,267 | $216 | +0.13% |
| Q4 2021 | 2021-12-31 | $165,429 | $378 | +0.23% |
| Q3 2021 | 2021-09-30 | $165,051 | $0 | 0.00% |
| Q2 2021 | 2021-06-30 | $165,051 | −$8,892 | −5.11% |
| Q1 2021 | 2021-03-31 | $165,051 | −$8,892 | −5.11% |
| Q4 2020 | 2020-12-31 | $165,051 | — | — |
| Q3 2020 | 2020-09-30 | $165,051 | — | — |
| Q2 2020 | 2020-06-30 | $173,943 | — | — |
| Q1 2020 | 2020-03-31 | $173,943 | — | — |
Greenwich LifeSciences stock-based compensation trends
Over the last five fiscal years, Greenwich LifeSciences's stock-based compensation increased from $677,988 to $6.8M, a change of $6.1M. The latest reported quarter, Q2 2026, shows $1.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Greenwich LifeSciences source filings ↗